Bayer CB prompts trade to allay volatility after Monsanto cancer case
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Derivatives

Bayer CB prompts trade to allay volatility after Monsanto cancer case

Bayer PA

Equity strategists at a bulge bracket bank are foreseeing volatility in Bayer’s share price around the time its €4bn mandatorily convertible bond matures next year, particularly because of its legal problems over a Monsanto weedkiller, and are pitching clients a strategy to profit from this, writes Costas Mourselas.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Related articles

Gift this article